- Alliance to Focus on Novel, Targeted Small Molecule Cancer Therapeutics
in Two Key Programs -
GAITHERSBURG, Md. and CAMBRIDGE, Mass., Aug. 28 /PRNewswire-FirstCall/ --
MedImmune, Inc. (Nasdaq: MEDI) and Infinity Pharmaceuticals, Inc. today
announced that they have entered into an agreement to jointly develop and
commercialize novel small molecule cancer drugs targeting Heat Shock Protein
90 (Hsp90) and the Hedgehog cell-signaling pathway. In preclinical studies,
Hsp90 and the Hedgehog pathway appear to be implicated in the growth and
survival of a broad range of blood-related and solid tumor types. IPI-504, the
most advanced of the drug candidates included in the agreement, is an Hsp90
inhibitor that has thus far been studied in two disease-focused Phase 1
"Hsp90 and Hedgehog are among the most attractive targeted therapy
opportunities in cancer research today, and the Infinity programs have a very
strong competitive position," said Edward T. Mathers, MedImmune's executive
vice president, corporate development and venture. "With IPI-504, we have a
promising drug candidate with already-established preclinical in vivo proof of
concept and the potential to reach the market by 2010. In collaboration with
Infinity, we plan to accelerate development of the intravenous formulation of
IPI-504, as well as to expand into additional tumor types. In addition, we
expect to be able to commence clinical testing of the next generation oral
formulation of IPI-504, as well as an oral formulation of a hedgehog inhibitor
within the next 12 to 18 months."
Under the terms of the agreement, MedImmune and Infinity will share
equally all costs and profits from the development and commercialization of
any future products. MedImmune will provide Infinity a one-time upfront
payment of $70 million for co-exclusive, shared rights to the Hsp90 and
Hedgehog pathway product development programs. In addition, Infinity could
receive up to an additional $430 million in milestone payments related to the
companies' achieving certain late-stage clinical development and sales targets
for any future products resulting from the collaboration.
For each of the Hsp90 and Hedgehog pathway programs, Infinity will retain
primary responsibility for discovery, preclinical development and
translational clinical development of products through proof-of-concept in
humans. MedImmune and Infinity will jointly conduct clinical development
through first product approval. MedImmune will lead worldwide regulatory
strategy as well as sales and marketing of resulting products; Infinity
retains an option to co-promote any future products in the United States,
contributing up to 35 percent of the total promotional effort.
"This collaboration with MedImmune allows Infinity to accelerate and
maximize the development of our most advanced product candidates while
enabling us to share fully in the potential value creation of these products,"
said Adelene Q. Perkins, Infinity's executive vice president and chief
business officer. "We believe that MedImmune's established clinical, sales,
and marketing capabilities are a strong complement to Infinity's expertise in
novel small molecule drug discovery and development."
About Hsp90 and IPI-504
IPI-504 is Infinity's proprietary small molecule therapeutic drug
candidate that, in preclinical studies, potently and selectively inhibited
Hsp90, thereby killing cancer cells. Hsp90 is an emerging therapeutic target
of interest for the treatment of cancer. Proteins are the mainstay of
structural and signaling elements of all cells. Hsp90 functions to stabilize
and maintain the activity of proteins in the cancer cell, thereby allowing a
cancer cell to survive despite an abundance of misfolded and unstable
proteins. Inhibition of Hsp90 has broad therapeutic potential for the
treatment of patients with solid tumors and blood-related cancers, including
cancers that are resistant to other drugs.
IPI-504 preferentially targets and accumulates in tumor tissues, sparing
healthy tissues. In preclinical studies it has demonstrated a broad potential
to treat certain cancers as both a single agent as well as in combination with
existing anti-cancer drugs. The water-based formulation of IPI-504 is easy to
deliver as an intravenous infusion. Infinity is currently conducting two Phase
1 clinical trials with intravenous formulations of IPI-504. In July 2005,
Infinity initiated the first of these Phase 1 clinical trials in refractory
multiple myeloma. In December 2005, Infinity initiated the second Phase 1
clinical trials with IPI-504 in refractory gastrointestinal stromal tumors
(GIST). Infinity has also begun developing an oral formulation of IPI-504,
which if successful, could be a more convenient route of administration for
About the Hedgehog Pathway
The Hedgehog cell-signaling pathway is normally active during embryonic
development regulating tissue and organ formation. However, aberrant
activation of the Hedgehog pathway in adults has been implicated in many of
the most deadly cancers, including pancreatic cancer, prostate cancer, small
cell lung cancer, breast cancer, and certain brain cancers. The activation of
this pathway is necessary for many of these cancers to proliferate and
survive. In addition to the role that the Hedgehog pathway plays in enabling
the survival and proliferation of cancer cells, recent evidence also points to
an important role for the Hedgehog pathway in cancer stem cells. Cancer stem
cells are believed to be the progenitor cells that allow tumors to survive
despite treatment with conventional chemotherapeutics agents.
Infinity's most advanced drug candidates are novel, proprietary
systemically administered agents that have demonstrated in preclinical studies
the ability to potently and selectively inhibit the Hedgehog pathway. Certain
of these agents have demonstrated efficacy in multiple preclinical animal
models of cancer as a single agent and are well tolerated in these models.
Impact to MedImmune's 2006 Financial Guidance
The estimated 2006 financial impact of the Infinity agreement to
MedImmune's previously stated earnings guidance range of $0.30 to $0.35 per
diluted share, before stock option expense, is a reduction of approximately
$0.19 per diluted share, primarily due to the one-time upfront payment of $70
million. However, the impact of this transaction may be partially offset by
gains MedImmune may receive from other in-process business transactions that
have the potential to be successfully completed by the end of 2006.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical
options for physicians, rewarding careers to employees, and increased value to
shareholders. Dedicated to advancing science and medicine to help people live
better lives, the company is focused on the areas of infectious diseases,
cancer and inflammatory diseases. With more than 2,300 employees worldwide,
MedImmune is headquartered in Maryland. For more information, visit the
company's website at http://www.medimmune.com.
About Infinity Pharmaceuticals, Inc.
Infinity Pharmaceuticals is an innovative cancer drug discovery and
development company that is seeking to leverage its strength in small molecule
drug technologies to discover, develop, and deliver to patients first-in-class
or best-in-class medicines for the treatment of cancer and related conditions.
The company announced on April 12, 2006 a definitive agreement to merge with
Discovery Partners International, Inc. (Nasdaq: DPII).
Additional Information about the DPI-Infinity Merger and Where to Find It
In connection with the proposed merger between Discovery Partners
International, Inc. (DPI) and Infinity, on August 7, 2006, DPI filed an
amended registration statement on Form S-4 that contains a proxy
statement/prospectus, which registration statement has been declared effective
by the SEC. Investors and security holders of DPI and Infinity are urged to
read the proxy statement/prospectus (including any amendments or supplements
to the proxy statement/prospectus) regarding the proposed merger because it
contains important information about DPI, Infinity and the proposed merger.
Security holders will be able to obtain a copy of the proxy
statement/prospectus, as well as other filings containing information about
DPI and Infinity, without charge, at the SEC's Internet site
(http://www.sec.gov). Copies of the proxy statement/prospectus can also be
obtained, without charge, by directing a request to Discovery Partners
International, Inc., 9640 Towne Centre Drive, San Diego, CA 92121, Attention:
Investor Relations, Telephone: (858) 455-8600.
Participants in the Solicitation
DPI and its directors and executive officers and Infinity and its
directors and executive officers may be deemed to be participants in the
solicitation of proxies from the stockholders of DPI in connection with the
proposed merger of DPI with Infinity. Information regarding the special
interests of these directors and executive officers in the merger transaction
is included in the proxy statement/prospectus referred to above. Additional
information regarding the directors and executive officers of DPI is also
included in DPI's proxy statement for its 2006 Annual Meeting of Stockholders,
which was filed with the SEC on April 6, 2006. This document is available free
of charge at the SEC's web site (www.sec.gov) and from Investor Relations at
DPI at the address described above.
This announcement contains, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties, in
particular, related to the research and development of future small molecule
products. Such statements reflect the current views of MedImmune and/or
Infinity management and are based on certain assumptions. Actual results
could differ materially from those currently anticipated as a result of a
number of factors, including risks and uncertainties discussed in MedImmune's
filings with the U.S. Securities and Exchange Commission and in the
registration statement on Form S-4 that was filed by DPI on May 24, 2006, and
subsequently amended, in connection with the proposed merger between DPI and
Infinity. There can be no assurance that such development efforts will
succeed, that the products will receive required regulatory clearance or, even
if such regulatory clearance is received, that the subsequent products will
ultimately achieve commercial success.
SOURCE MedImmune, Inc.
CONTACT: Media: Jamie Lacey, +1-301-398-4035, or Investors: Peter Vozzo,
+1-301-398-4358, both of MedImmune, Inc.; or Media: Monique Allaire,
+1-617-453-1105, or Investors: John Evans, +1-617-453-1254, both of Infinity